PCRX PACIRA BIOSCIENCES INC revenue, earnings and financials
For the quarter ended June 30, 2026, PACIRA BIOSCIENCES INC reported revenue of $192M (up 6.2% from a year earlier), net income of $4.65M and diluted EPS of $0.12; over the last four quarters revenue was $746M and net income $14.6M; for the fiscal year ended December 2025 revenue was $726M, up 3.6% on the year before.
PCRX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $726M, gross profit n/a, operating income $19.2M, net income $7.00M (margin 1.0%), EPS $0.16
- Fiscal year ended Dec 2024: revenue $701M, gross profit n/a, operating income −$73.4M, net income −$99.6M (margin -14.2%), EPS −$2.15
- Fiscal year ended Dec 2023: revenue $675M, gross profit n/a, operating income $87.7M, net income $42.0M (margin 6.2%), EPS $0.89
- Fiscal year ended Dec 2022: revenue $667M, gross profit n/a, operating income $60.0M, net income $15.9M (margin 2.4%), EPS $0.34
- Fiscal year ended Dec 2021: revenue $542M, gross profit n/a, operating income $89.9M, net income $42.0M (margin 7.8%), EPS $0.92
PCRX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $192M (up 6.2% year over year), net income $4.65M, EPS $0.12
- Quarter ended Mar 31, 2026: revenue $177M (up 5.0% year over year), net income $2.92M, EPS $0.07
- Quarter ended Dec 31, 2025 (from the annual report): revenue $197M (up 5.1% year over year), net income $1.60M, EPS $0.05
- Quarter ended Sep 30, 2025: revenue $180M (up 6.5% year over year), net income $5.43M, EPS $0.12
- Quarter ended Jun 30, 2025: revenue $181M (up 1.7% year over year), net income −$4.85M, EPS −$0.11
- Quarter ended Mar 31, 2025: revenue $169M (up 1.1% year over year), net income $4.81M, EPS $0.10
- Quarter ended Dec 31, 2024 (from the annual report): revenue $187M (up 3.3% year over year), net income $16.0M, EPS $0.38
- Quarter ended Sep 30, 2024: revenue $169M (up 2.8% year over year), net income −$143M, EPS −$3.11
- Quarter ended Jun 30, 2024: revenue $178M (up 5.0% year over year), net income $18.9M, EPS $0.39
- Quarter ended Mar 31, 2024: revenue $167M (up 4.2% year over year), net income $8.98M, EPS $0.19
- Quarter ended Dec 31, 2023 (from the annual report): revenue $181M (up 5.4% year over year), net income $24.9M, EPS $0.58
- Quarter ended Sep 30, 2023: revenue $164M (down 2.1% year over year), net income $10.9M, EPS $0.23
- Quarter ended Jun 30, 2023: revenue $169M (up 0.0% year over year), net income $25.8M, EPS $0.51
- Quarter ended Mar 31, 2023: revenue $160M (up 1.5% year over year), net income −$19.5M, EPS −$0.43
- Quarter ended Dec 31, 2022 (from the annual report): revenue $172M (up 8.0% year over year), net income −$10.1M, EPS −$0.19
- Quarter ended Sep 30, 2022: revenue $167M (up 31.1% year over year), net income −$693K, EPS −$0.02
- Quarter ended Jun 30, 2022: revenue $169M (up 24.9% year over year), net income $19.9M, EPS $0.40
- Quarter ended Mar 31, 2022: revenue $158M (up 32.7% year over year), net income $6.83M, EPS $0.15
- Quarter ended Dec 31, 2021 (from the annual report): revenue $159M, net income −$5.11M, EPS −$0.12
- Quarter ended Sep 30, 2021: revenue $128M, net income $17.7M, EPS $0.39
PCRX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $152M, share buybacks $148M
- Fiscal year ended Dec 2024: operating cash flow $189M, share buybacks $25.0M
- Fiscal year ended Dec 2023: operating cash flow $155M, share buybacks $0
- Fiscal year ended Dec 2022: operating cash flow $145M, share buybacks $0
- Fiscal year ended Dec 2021: operating cash flow $126M, share buybacks n/a
PCRX balance sheet
- Jun 30, 2026: cash $206M, total assets $1.24B, total liabilities $572M, shareholders' equity $672M, long-term debt $363M
- Mar 31, 2026: cash $144M, total assets $1.21B, total liabilities $555M, shareholders' equity $654M, long-term debt $368M
- Dec 31, 2025: cash $159M, total assets $1.26B, total liabilities $572M, shareholders' equity $693M, long-term debt $372M
- Sep 30, 2025: cash $148M, total assets $1.30B, total liabilities $570M, shareholders' equity $727M, long-term debt $377M
- Jun 30, 2025: cash $300M, total assets $1.54B, total liabilities $779M, shareholders' equity $758M
- Mar 31, 2025: cash $284M, total assets $1.59B, total liabilities $788M, shareholders' equity $799M
- Dec 31, 2024: cash $277M, total assets $1.55B, total liabilities $775M, shareholders' equity $778M, long-term debt $384M
- Sep 30, 2024: cash $246M, total assets $1.52B, total liabilities $772M, shareholders' equity $750M
What is PCRX's revenue?
PACIRA BIOSCIENCES INC reported $746M of revenue over its last four quarters, through June 30, 2026.
Is PCRX profitable?
Yes. PACIRA BIOSCIENCES INC earned $14.6M over the last four quarters.
What is PCRX's EPS?
Diluted earnings per share over the last four quarters were $0.36; $0.12 in the latest quarter.